INTRODUCTION
============

Studies of tumour suppressor genes responsible for rare inherited cancer syndromes have revealed fundamental processes in cell biology as well as the molecular origins and pathogenesis of familial and sporadic forms of cancer. Germline mutations in the von Hippel-Lindau (*VHL*) tumour suppressor gene cause VHL disease, which is characterized by the development of tumours in multiple organs including the central nervous system (CNS), retina, adrenal gland, and kidney \[[@B1], [@B2]\]. Although the incidence of VHL disease is infrequent with an approximate incidence of 1 in 40,000 individuals, bi-allelic inactivation of the *VHL* gene has been documented in a majority of sporadic cerebellar haemangioblastomas and renal clear cell carcinomas (RCC) \[[@B1]\]. RCC is the most common form of kidney cancer and is the main cause of death in VHL patients \[[@B3]\].

CLONING OF THE VHL GENE
=======================

Chromosome 3p deletions are common in a variety of solid tumours including renal carcinomas \[[@B4], [@B5]\]. Furthermore, several studies identified kindreds with early-onset, bilateral, and multifocal RCCs having germline translocations of 3p to chromosomes 6, 8, or 11 \[[@B6], [@B7], [@B8]\]. In an effort to isolate the kidney cancer-susceptibility gene on chromosome 3p, scientists studied the hereditary kidney cancer associated with VHL disease, supposing that the *VHL* gene may be associated with the nonhereditary form of kidney cancer. In 1988, Seizinger and colleagues used genetic linkage analysis to map the *VHL* gene to a 6 to 8 centimorgan (cM) region of chromosome 3p25 to 3p26 \[[@B9]\]. The putative *VHL* locus was then narrowed to a 4 cM interval by multipoint linkage analysis, and pulse-field gel electrophoresis was subsequently used to further demarcate the minimal genomic region commonly deleted among unrelated VHL kindreds \[[@B10], [@B11]\]. Armed with this information, Latif and colleagues cloned the *VHL* gene in 1993 \[[@B12]\].

VHL GENOTYPE-PHENOTYPE CORRELATIONS
===================================

The detection of intragenic mutations that segregated with the disease in VHL kindreds confirmed the authenticity of the *VHL* gene. Furthermore, tumour-derived *VHL* gene mutations have been identified throughout the *VHL* open reading frame with the exception of the sequences encoding the first 54 amino acids \[[@B1], [@B2]\]. Despite the mutational heterogeneity, striking correlations between certain germline mutations and specific clinical manifestations of the disease are emerging \[[@B1], [@B2]\]. Such genotype-phenotype correlations have led to the classification of the VHL disease into subcategories depending on their propensity to develop phaeochromocytoma: Type 1 families have a low risk and Type 2 families have a high risk of developing phaeochromocytoma. Type 2 is further subdivided into 2a (low risk of renal carcinoma), 2b (high risk of renal carcinoma), and 2c (develop exclusively phaeochromocytoma without the other stigmata of the disease). Germline mutations associated with Type 1 disease are usually deletions, microinsertions, and nonsense mutations, whereas those mutations associated with Type 2 disease are almost invariably missense mutations \[[@B13]\].

VEC MULTIPROTEIN COMPLEX
========================

Neither the primary nucleotide nor the amino acid sequence of pVHL had any significant homology to proteins with known functions. Thus, to discern the function(s) of pVHL, several groups independently sought to identify the cellular proteins that bound to pVHL, with the supposition that pVHL-associated proteins might have identifiable functions. It is now evident that pVHL forms a multiprotein complex (VEC) with elongin B, elongin C, Cullin (Cul) 2, and Rbx1 (also called ROC1 or Hrt1) \[[@B14]\]. Remarkably, the VEC complex bears striking structural homology with a known class of E3 ubiquitin ligases called the SCF \[[@B14]\]. The E3 ubiquitin ligases target proteins for ubiquitylation, which marks them for proteolysis by the 26S proteasome (see Figure [1](#F1){ref-type="fig"}). The SCF complex consists of Skp1 (S-phase kinase-associated protein 1, suppressor of Cdk-inhibitor proteolysis and of kinetochore protein), Cdc53 or Cul1, Rbx1, and a substrate-conferring F-box protein (so called because of a collinear motif, first identified in cyclin F) (Figure [1](#F1){ref-type="fig"}).

Cul2 bears significant sequence and structural similarities to the yeast *Cullin*, Cdc53 \[[@B14]\]. Elongin C is homologous to Skp1 and performs an analogous Skp1-like role of bridging the F-box protein to the rest of the complex \[[@B14]\]. Rbx1 is a common component of VEC and SCF complexes \[[@B14]\]. The recently solved crystal structure of pVHL suggests that it might have a function analogous to that of an F-box protein \[[@B15]\]. Specifically, Pavletich and co-workers showed that pVHL has two domains: an α domain and a β domain \[[@B15]\]. The α domain is essential for directly binding elongin C, via the elongin B/C-binding motif, which loosely resembles the F-box. Elongin C is associated with elongin B, Cul2, and Rbx1. Thus, pVHL binding to elongin C via the α domain promotes the nucleation of the VEC complex. The β domain is predicted to function as a putative substrate-docking site. Notably, disease-associated mutations found in VHL kindreds map to the surface residues of α and β domains, suggesting the importance of both domains in the tumour suppressor function of pVHL. Thus, the structural homology between VEC and SCF complexes led to the notion that pVHL may have a role in targeting certain protein(s) for ubiquitin-mediated proteolysis (Figure [1](#F1){ref-type="fig"}).

VHL DISEASE-ASSOCIATED TUMOURS AND VHL ANIMAL MODEL
===================================================

A vital clue to the potential downstream substrate or target of VEC came from the phenotypic observations of VHL disease-associated tumours. That is, tumours associated with VHL disease, such as retinal angiomas, cerebellar and spinal haemangioblastomas, and RCC, are known to be hypervascular \[[@B14]\]. This condition has been attributed primarily to the inability to suppress the expression of angiogenic peptides such as vascular endothelial growth factor (VEGF) that are normally induced by hypoxia \[[@B1], [@B14]\]. In support of this observation, transformed cell lines lacking functional pVHL express elevated levels of VEGF even under normal oxygen tension \[[@B1], [@B2], [@B14]\]. Furthermore, Haase et al generated conditional *VHL* knockout mice using the Cre-loxP-mediated recombination, in which *VHL* can be inactivated in a spatially and temporally controlled manner \[[@B16]\]. *VHL* −/− mice are not viable, precluding the study of pVHL inactivation in adults \[[@B17]\]. Targeted disruption of *VHL* in the liver resulted in severe steatosis, numerous blood-filled vascular cavities, and foci of increased vascularization within the hepatic parenchyma \[[@B16]\]. Notably, hypoxia-inducible mRNAs were markedly increased \[[@B16]\]. Thus, the conditional mouse model for VHL disease underscores the significance of pVHL in the regulation of hypoxia-inducible genes.

HIF, THE FIRST TARGET OF VEC
============================

A transcriptional complex called the hypoxia-inducible factor (HIF) is a global regulator of oxygen-dependent gene expression, including the aforementioned *VEGF*, which is upregulated during a cellular response to hypoxia \[[@B18], [@B19]\]. HIF is a heterodimeric transcriptional activator, composed of α and β subunits, that binds DNA in a sequence-specific manner. Whereas the α subunit is labile under normal oxygen tension, the β subunit (also known as aryl hydrocarbon receptor nuclear translocator \[ARNT\]) is abundantly expressed independently of oxygen tension. The α subunit is subjected to ubiquitin-mediated degradation through a stretch of residues referred to as the oxygen-dependent degradation (ODD) domain. Hence, the regulation of HIF is through the control of the unstable α subunit \[[@B18], [@B19]\]. Recently, Maxwell and colleagues observed that the α subunit is stabilized in cells devoid of wild-type pVHL \[[@B20]\]. More importantly, they found that HIFα subunits are physically associated with pVHL \[[@B20]\]. These observations suggested that the α subunits of HIF are the physiological targets of pVHL.

TAGGING HIF WITH UBIQUITIN BY VEC
=================================

HIFα subunits are observed to bind directly to the predicted β domain of pVHL (Figure [1](#F1){ref-type="fig"}) \[[@B21], [@B22], [@B23]\]. Intriguingly, the ODD domain of HIFα subunit is both necessary and sufficient for binding to pVHL \[[@B21], [@B22], [@B23]\]. Furthermore, pVHL is specifically required for the ubiquitylation of HIFα subunits in vitro via the ODD domain \[[@B21], [@B22], [@B23]\]. Vascular tumour-derived mutations in the adapter α domain or the substrate-docking β domain of pVHL abolished the ubiquitylation of HIFα subunits, reiterating the concerted requirement of pVHL to form (1) a multiprotein ubiquitin ligase complex via elongin B/C-binding site within the α domain and (2) an efficient recognition of HIFα subunits via the β domain \[[@B22]\]. Hypoxia mimetics attenuated the ubiquitin ligase activity of pVHL, reinforcing the notion that VEC targets HIFα under the selective presence of oxygen \[[@B22]\].

It is now known that in the presence of oxygen, iron, and oxoglutarate, HIFα is hydroxylated at highly conserved proline residues, at positions 402 and 564 \[[@B24], [@B25], [@B26]\]. Epstein and co-workers found that in *Caenorhabditis elegans* this process is accomplished by a novel EGL-9 dioxygenase \[[@B27]\]. There are three known mammalian EGL-9 homologues called PHD/HPH (prolyl hydroxylase domain-containing protein, also referred to as HIF prolyl hydroxylase) 1, 2, and 3, that perform an analogous function \[[@B27], [@B28]\]. Importantly, hydroxylation of these proline residues is both sufficient and necessary for binding to pVHL \[[@B24], [@B25], [@B26]\]. Thus, under normal oxygen tension or normoxia, pVHL in an ubiquitin ligase complex selectively ubiquitylates the prolyl hydroxylated HIFα \[[@B24], [@B25], [@B26]\]. Importantly, the disease-associated pVHLs are unable to target the prolyl hydroxylated HIFα for ubiquitin-mediated proteolysis under normoxia \[[@B24]\]. Consequently, HIFα subunits and the downstream targets of HIF transcription factor are overexpressed in cells lacking wild-type pVHL, irrespective of ambient oxygen tension. These observations establish pVHL as a vital component of a bona fide E3 ubiquitin ligase complex that marks prolyl hydroxylated HIFα subunits with a polyubiquitin chain for destructive targeting by the 26S proteasome (see Figure [2](#F2){ref-type="fig"}).

It should be noted that prolyl hydroxylation as a posttranslational signal for recognition by an F-box protein represents the first exception to the current dogma of phosphorylation-dependent recognition of target proteins by the SCF complexes. Moreover, this raises the question of what other protein-protein interactions and biochemical processes are regulated by prolyl hydroxylation.

MODULATION OF VEC FUNCTION BY NEDD8
===================================

Despite our recent understanding of the oxygen-dependent pathway that controls HIFα recognition by VEC, the underlying mechanisms governing the actual activity of VEC remain unclear. Genetic experiments with *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, and *Arabidopsis thaliana* showed that an ubiquitin-like protein Rub-1 covalently modified Cdc53 and affected the function of SCF \[[@B29]\]. Likewise, the mammalian Rub-1 homologue NEDD8 is also conjugated to Cul1 in mammalian SCF and Cul2 in VEC \[[@B30], [@B31]\]. The E2 NEDD8-conjugating enzyme, Ubc12, is required for the neddylation of Cullins including Cul1 and 2 \[[@B32], [@B33]\]. Moreover, the neddylation of Cul1 or 2 increases the E3 ubiquitin ligase activities of SCF or VEC, respectively, in vitro \[[@B34], [@B35], [@B36]\] and in vivo \[[@B34]\]. However, how Cul2 modification by NEDD8 enhances the E3 activity of VEC is unclear. One possibility is that NEDD8 conjugation to Cul2 increases the affinity of Cul2 to E2 ubiquitin-conjugation enzyme. In support of this notion, Kawakami and colleagues, recently demonstrated that NEDD8 conjugation to Cul1 enhances the affinity of SCF to the E2 ubiquitin-conjugation enzyme Ubc4 \[[@B37]\].

THE "VHL-PATHWAY" AND FUTURE DIRECTIONS
=======================================

Recent insights into the molecular mechanisms governing the function of pVHL have provided significant understanding of the "VHL-pathway." In the presence of cellular dioxygen, the newly identified dioxygenases, PHD/HPH 1, 2, and 3, selectively hydroxylate the evolutionarily conserved proline residues on HIFα subunits, which are then selectively recognized by VEC via pVHL \[[@B27], [@B28]\]. VEC in concert with a cognate E2 ubiquitin-conjugating enzyme ubiquitylates the prolyl hydroxylated HIFα subunits for subsequent destruction by the 26S proteasome. During hypoxia, HIFα is no longer modified by PHD/HPHs and consequently escapes ubiquitin-mediated proteolysis. The now stable HIFα dimerizes with HIFβ to form the transcription factor HIF, which binds to hypoxia responsive elements to trigger the transcriptional activation of numerous hypoxia-inducible genes, ultimately resulting in the synthesis of proteins that mediate the physiological responses to hypoxia (Figure [2](#F2){ref-type="fig"}). Thus, the "VHL-pathway" is intricately tied to the oxygen sensing mechanisms in multicellular organisms.

Further elucidation of the players that take part in the "VHL-pathway" will undoubtedly benefit the progress in the development of pharmacological agents to treat not only VHL patients but also those displaying tumours frequently associated with VHL disease, such as vascular tumours of the CNS and kidney. Moreover, the inability to maintain proper oxygen homeostasis is the one unifying the pathophysiology of stroke, cardiovascular diseases, chronic lung diseases, and cancer, which represent the most common causes of death in developed nations \[[@B38]\]. Thus, studies into the "VHL-pathway" show great promise to aid in the design of synthetic drugs to block the progression of broad range of human diseases.

Figures and Tables
==================

![Comparison between the modular SCF and VEC complexes. SCF complex is composed of Skp1, Cdc53, Rbx1, and an F-box protein. Substrate specificity is conferred by the F-box protein. For example, SCF^Skp2^ in concert with E2 ubiquitin-conjugating enzyme Cdc34 selectively targets the phosphorylated p27, as well as E2F-1 and Cyclin E, for ubiquitination. VEC complex is composed of Skp1-like elongin C, Cdc53 homologue Cul2, common Rbx1, ubiquitin-like elongin B and an F-box protein pVHL. The SCF-like VEC complex in concert with a cognate E2 targets prolyl hydroxylated HIFα subunits for ubiquitylation. NEDD8 conjugation to Cul1 or Cul2 enhances the E3 activity of both SCF and VEC complexes. Replacement of the F-box protein pVHL with SOCS1 forms SEC that specifically targets VAV or Tel-Jak. B represents elongin B; C represents elongin C; S represents Skp1; R represents Rbx1; N represents NEDD8.](20505.fig.001){#F1}

![Oxygen-dependent gene regulation via the "VHL-pathway." In the presence of dioxygen, iron, and oxoglutarate, prolyl hydroxylases PHD/HPH 1,2, and 3 hydroxylate the α subunit of HIF on proline residues 402 and 564. The hydroxylated HIFα subunit is recognized by the VEC complex for ubiquitylation. In reduced oxygen tension, HIFα is no longer hydroxylated and thereby escapes ubiquitin-mediated proteolysis. HIFβ binds to the stable HIFα to form HIF, which promotes the transcriptional activation of numerous hypoxia-inducible genes (HIGs). Protein synthesis of HIGs results in various physiological responses to hypoxia. HRE represents hypoxia-responsive element; ECM represents extracellular matrix.](20505.fig.002){#F2}

ACKNOWLEDGMENTS
===============

We thank Drs Jeremy Mogridge, Douglas Templeton, and Meredith Irwin for helpful discussions. This work was supported by the National Cancer Institute of Canada with funds from the Terry Fox Run. MO is a Canada Research Chair in Molecular Oncology.
